Arcus Biosciences annual ebitda margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcus Biosciences EBITDA Margin Growth & History (RCUS)
Arcus Biosciences's ebitda margin was −1,139.39% for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,139.39% | −511.94 pp |
| 2024 | 2024-12-31 | −627.45% | +269.85 pp |
| 2023 | 2023-12-31 | −897.30% | −176.24 pp |
| 2022 | 2022-12-31 | −721.05% | −736.20 pp |
| 2021 | 2021-12-31 | 15.14% | +170.27 pp |
| 2020 | 2020-12-31 | −155.13% | +412.41 pp |
| 2019 | 2019-12-31 | −567.54% | +45.35 pp |
| 2018 | 2018-12-31 | −612.89% | +2984.35 pp |
| 2017 | 2017-12-31 | −3,597.24% | — |
Arcus Biosciences quarterly ebitda margin
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −281.82% | −206.82 pp |
| Q1 2026 | 2026-03-31 | −1,885.71% | −398.21 pp |
| Q4 2025 | 2025-12-31 | −1,009.09% | −574.31 pp |
| Q3 2025 | 2025-09-30 | −2,333.33% | −861.90 pp |
| Q2 2025 | 2025-06-30 | −75.00% | +870.45 pp |
| Q1 2025 | 2025-03-31 | −1,487.50% | −1357.50 pp |
| Q4 2024 | 2024-12-31 | −434.78% | — |
| Q3 2024 | 2024-09-30 | −1,471.43% | −1224.55 pp |
| Q2 2024 | 2024-06-30 | −945.45% | −666.14 pp |
| Q1 2024 | 2024-03-31 | −130.00% | +206.00 pp |
| Q3 2023 | 2023-09-30 | −246.88% | −40.81 pp |
| Q2 2023 | 2023-06-30 | −279.31% | −31.16 pp |
| Q1 2023 | 2023-03-31 | −336.00% | +30.67 pp |
| Q3 2022 | 2022-09-30 | −206.06% | +609.64 pp |
| Q2 2022 | 2022-06-30 | −248.15% | +547.92 pp |
| Q1 2022 | 2022-03-31 | −366.67% | +393.79 pp |
| Q4 2021 | 2021-12-31 | 79.65% | — |
| Q3 2021 | 2021-09-30 | −815.70% | −819.25 pp |
| Q2 2021 | 2021-06-30 | −796.07% | +1751.82 pp |
| Q1 2021 | 2021-03-31 | −760.46% | +814.28 pp |
| Q3 2020 | 2020-09-30 | 3.55% | +1286.35 pp |
| Q2 2020 | 2020-06-30 | −2,547.89% | −927.31 pp |
| Q1 2020 | 2020-03-31 | −1,574.74% | −556.46 pp |
| Q4 2019 | 2019-12-31 | −169.25% | +625.88 pp |
| Q3 2019 | 2019-09-30 | −1,282.80% | −1020.74 pp |
| Q2 2019 | 2019-06-30 | −1,620.57% | −420.65 pp |
| Q1 2019 | 2019-03-31 | −1,018.29% | −15.81 pp |
| Q4 2018 | 2018-12-31 | −795.13% | +207.35 pp |
| Q3 2018 | 2018-09-30 | −262.06% | +13501.13 pp |
| Q2 2018 | 2018-06-30 | −1,199.92% | — |
| Q1 2018 | 2018-03-31 | −1,002.48% | — |
| Q4 2017 | 2017-12-31 | −1,002.48% | — |
| Q3 2017 | 2017-09-30 | −13,763.19% | — |
Arcus Biosciences ebitda margin trends
Over the last five fiscal years, Arcus Biosciences's ebitda margin decreased from −155.13% to −1,139.39%, a change of −984.27 percentage points. The latest reported quarter, Q2 2026, shows −281.82%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗Community posts
Arcus sets $17.50 share price for $250 million equity financing
Arcus Biosciences ($RCUS) priced an underwritten public offering of 14,285,715 new common shares at $17.50 apiece, targeting approximately $250 million in gross proceeds. The company is selling all of the shares, so the financing would add ...
Arcus reports additional kidney-cancer data supporting casdatifan development
Arcus Biosciences ($RCUS) released additional results from the ARC-20 program evaluating casdatifan in kidney cancer. Across pooled monotherapy cohorts involving 121 heavily pretreated patients, median overall survival was 35 months, median ...
